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The costs were valued in terms of year 2004 Ringgit Malaysia
(RM). Sensitivity analyses were performed. RESULTS: Erythro-
poietin therapy improved the mean haemoglobin level of
anaemic haemodialysis patients by 9.39% and CAPD patients
by 8.48% at the range of 8 to 10 g/dl. Overall life expectancy 
on dialysis was 10.13 years with superior life expectancy for
haemodialysis (11.37 years) compared to CAPD (7.94 years).
The cost per quality-adjusted life years was RM43,000 for
haemodialysis and RM41,000 for CAPD. The incremental
QALYs gained for haemodialysis and CAPD patients at haemo-
globin baseline were 2.04 and 0.27, respectively. The incremen-
tal cost per QALY gained of EPO was RM66,000 and
RM137,000 for haemodialysis and CAPD patients, respectively
at the same average baseline haemoglobin level between 8 g/dl
and 10 g/dl. CONCLUSION: With the current state of utilisa-
tion of EPO therapy in the Ministry of Health of Malaysia
setting, haemodialysis is more cost effective modality compared
to CAPD.
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OBJECTIVE: Three quarters of patients with CKD and anemia
are not treated with ESP prior to End Stage Renal Disease. The
capacity to provide anemia treatment in nephrology practices
may be a hindrance to early initiation of treatment in these
patients. METHODS: A decision tree was developed, simulating
annual time savings associated with ESP administration when
weekly (QW) administration is transitioned to less frequent
administration. Parameter estimates were derived from a cross-
sectional observational study assessing time utilized to adminis-
ter ESP injections to CKD anemic patients. The model has two
arms, simulating treatment over a one year period; arm “A” of
the model has four transition states which represent the fre-
quency of ESP administration (QW, Q2W (every two weeks),
QM (monthly), and “QW only”). In arm “A” 100% of the
patients start on a QW regimen. The ‘QW only’ state simulates
those patients whose hemoglobin cannot be stabilized on
extended dosing and fail transition to extended dosing. Arm “B”
has only one state, QW. RESULTS: At the end of the simulated
year, estimated ESP administration time was 263 minutes per
patient per year in arm “A” (QM) vs. 467 minutes in arm “B”
(QW). The difference in time between arm “B” and “A” results
in 3.4 hours less for arm “A”. In arm “A” 79% of patients were
in the Q4W state, 9% in Q2W, and 12% in QW and QW only.
On average, it took 3–4 months to extend the patient to QM.
CONCLUSIONS: The results of the model suggest that a
nephrology clinic could save, on average, 3.4 hours per patient
during the ﬁrst year by transitioning to less frequent ESP admin-
istration. Greater savings may be realized once the transition has
been completed, possibly providing increased capacity for treat-
ment of additional patients with CKD and anemia.
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OBJECTIVE: This study examined trends in physician-
prescribing of medications for anemia management of chronic
kidney disease (CKD) in outpatient settings in the United States.
METHODS: This cross-sectional study used data from the
National Ambulatory Medical Care Survey (NAMCS) from
1996 to 2003. Patients aged ≥18 years with chronic kidney
disease treated in the US outpatient settings were included in the
study sample. Ofﬁce visits were considered related to CKD if rel-
evant ICD-9 codes were recorded and if CKD was reported as
the reason for the visit. Similarly, ofﬁce visits were considered
related to anemia if anemia relevant ICD-9 codes were recorded
and if anemia was reported as the reason for the visit or labo-
ratory testing was ordered during the visits. Anemia medications
(Erythropoietic stimulating agents or iron replacement) were
retrieved using the NAMCS drug codes, and all analyses 
were weighted to make national estimates. RESULTS: There
were approximately 92 million weighted patient visits were made
for CKD in the outpatient settings from 1996 to 2003. Nearly
two-thirds (63%) of these visits were related to female and 54%
of these visits were by patient aged more than 65 years. Nephrol-
ogists accounted for 18% of the patient visits and 48% of the
patient reported having anemia. Only 10% of visits with anemia
resulted in a prescription for anemia medication (Erythropoietic
stimulating agents & iron replacements). There were no time-
related differences observed in these prescribing patterns. CON-
CLUSIONS: The ﬁndings of this study seem to suggest that few
visits with anemia are receiving anemia medications in US out-
patient settings, since most of the visits do not result in anemia
medication prescription.
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OBJECTIVES: Secondary hyperparathyroidism (SHPT) is a
common side effect of end-stage renal disease and is associated
with increased risk of fracture and cardiovascular events.
Cinacalcet is the ﬁrst of a new class of calcimimetic drugs, which
suppress parathyroid hormone (PTH) production. The aim of
this study is to estimate the cost-utility of cinacalcet in patients
with SHPT. Although there is convincing evidence of the posi-
tive impact of cinacalcet on serum biomarkers such as PTH, the
long-term cost and clinical implications of treatment are less
clear. METHODS: A Markov model was developed in Excel to
estimate differences in quality adjusted life years (QALYs) in
people with SHPT in end stage renal disease (ESRD) treated with
cinacalcet, compared to those receiving standard treatment
alone. The model was stratiﬁed by degree of disease progression.
Estimates of the effectiveness of cinacalcet were taken from a sys-
tematic review of the literature by the authors. Where possible,
other transition probabilities, costs and utilities all came from
published sources. Costs and beneﬁts were discounted at 3.5%
annually. The perspective of the UK National Health Service was
taken throughout. Extensive one-way and probabilistic sensitiv-
